

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity PRIMA BIOMED LIMITED (ASX:PRR)
ABN 90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Pete Meyers
Date of last notice	28 November 2014

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	1 October 2015
No. of securities held prior to change	1) 1,715,686 Ordinary Fully Paid Shares 2) 6,004,902 Performance Rights
Class	1) Ordinary Fully Paid shares 2) Performance Rights
Number acquired	2,573,529 Ordinary Fully Paid Shares
Number disposed	2,573,529 Performance Rights

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Nil</p> <p>The Performance Rights are issued as remuneration for services as a director as Mr Meyers is taking his fees entirely in Performance Rights in lieu of cash and in accordance with shareholder's approval obtained at Annual General Meeting on 14<sup>th</sup> November 2014.</p> <p>No amount is payable upon exercise of the Performance Rights for shares after vesting.</p>
<p><b>No. of securities held after change</b></p>	<p>1) 4,289,215 Ordinary Fully Paid Shares</p> <p>2) 3,431,373 Performance Rights</p>
<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>1) Acquiring 2,573,529 shares upon exercise of the second tranche of performance rights. One ordinary fully paid share was acquired for each Performance Right that vested.</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p><b>Detail of contract</b></p>	
<p><b>Nature of interest</b></p>	
<p><b>Name of registered holder (if issued securities)</b></p>	
<p><b>Date of change</b></p>	
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	
<p><b>Interest acquired</b></p>	
<p><b>Interest disposed</b></p>	

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

For personal use only

---

+ See chapter 19 for defined terms.